A

Agilent Technologies, Inc.
$137.91
-0.66 (-0.47%)
Mkt Cap 38.93B
Volume 836,095
52W Range 108.35-160.27
Sector Healthcare
Beta 1.25
EPS (TTM) 4.99
P/E Ratio 27.62
Revenue (TTM) 7.23B
Rev Growth (5Y) +5.4%
EPS Growth (5Y) +14.5%
AlphaVal · Fair Value
What we estimate one share is worth
$95.47
Overvalued strong signal
44.4% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
B
Stable Earnings Power
74.9 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 6.95B 6.51B 6.83B 6.85B 6.32B 5.34B 5.16B 4.91B 4.47B 4.20B 4.04B 4.05B
Net Income 1.30B 1.29B 1.24B 1.25B 1.21B 719.00M 1.07B 316.00M 684.00M 460.00M 401.00M 549.00M
EPS 4.59 4.44 4.22 4.19 3.98 2.33 3.41 0.98 2.12 1.42 1.20 1.65
Free Cash Flow 1.15B 1.37B 1.47B 1.02B 1.30B 802.00M 865.00M 910.00M 713.00M 654.00M 393.00M 506.00M
FCF / Share 4.07 4.73 5.01 3.41 4.26 2.60 2.75 2.83 2.21 2.01 1.18 1.52
Operating CF 1.56B 1.75B 1.77B 1.31B 1.49B 921.00M 1.02B 1.09B 889.00M 793.00M 491.00M 713.00M
Total Assets 12.73B 11.85B 10.76B 10.53B 10.71B 9.63B 9.45B 8.54B 8.43B 7.79B 7.48B 10.81B
Total Debt 3.35B 3.57B 2.73B 2.77B 2.73B 2.36B 2.41B 1.80B 2.01B 1.90B 1.66B 1.66B
Cash & Equiv 1.79B 1.33B 1.59B 1.05B 1.48B 1.44B 1.38B 2.25B 2.68B 2.29B 2.00B 2.22B
Book Value 6.74B 5.90B 5.84B 5.30B 5.39B 4.87B 4.75B 4.57B 4.83B 4.24B 4.16B 5.30B
Return on Equity 0.19 0.22 0.21 0.24 0.22 0.15 0.23 0.07 0.14 0.11 0.10 0.10
A News
Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Jul 23, 2026 04:00 AM · businesswire.com
Agilent Increases Its Investment in HALO X-ray Technologies
Jul 19, 2026 11:11 PM · businesswire.com
Dividend Champion, Contender, And Challenger Highlights: Week Of July 19
Jul 17, 2026 07:12 PM · seekingalpha.com
Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
Jul 14, 2026 04:00 AM · businesswire.com
Agilent Strengthens Biopharma Growth Prospects With AI Expansion
Jul 09, 2026 10:55 AM · zacks.com
Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis
Jul 08, 2026 04:00 AM · businesswire.com
Alpha and Omega Semiconductor Unveils AmpStack™ Packaging: A Leap Forward in MOSFET Power Density
Jul 07, 2026 07:00 AM · gurufocus.com
Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight
Jul 01, 2026 04:00 AM · businesswire.com
Why Is Agilent (A) Up 0.1% Since Last Earnings Report?
Jun 26, 2026 08:31 AM · zacks.com
Excellere Partners and GHO Capital complete sale of Biocare Medical to Agilent Technologies
Jun 25, 2026 04:06 AM · globenewswire.com